1. Novel diosgenin-amino acid-benzoic acid mustard trihybrids exert antitumor effects via cell cycle arrest and apoptosis.
- Author
-
Wang W, Li C, Chen Z, Zhang J, Ma L, Tian Y, Ma Y, Guo L, Wang X, Ye J, and Wang X
- Subjects
- A549 Cells, Amino Acids chemistry, Amino Acids pharmacology, Animals, Antineoplastic Agents chemical synthesis, Antineoplastic Agents chemistry, Benzoic Acid chemistry, Cell Proliferation drug effects, Chemistry, Pharmaceutical, Diosgenin chemistry, HCT116 Cells, Hep G2 Cells, Humans, MCF-7 Cells, Mitochondria drug effects, Mitochondria metabolism, Mustard Plant chemistry, Reactive Oxygen Species metabolism, Structure-Activity Relationship, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Zebrafish, Antineoplastic Agents pharmacology, Apoptosis drug effects, Benzoic Acid pharmacology, Cell Cycle Checkpoints drug effects, Diosgenin pharmacology
- Abstract
In discovering new powerful antitumor agents, two series of novel diosgenin-amino acid-benzoic acid mustard trihybrids (7a-7 g and 12a-12 g) were designed and synthesized. The antiproliferative activities were tested against five human tumor cell lines and one normal cell line using CCK-8 assays. Among the trihybrids, 12e was the most promising compound, which inhibited T24 cells with IC
50 value of 6.96 μM, and was stronger than its parent compound diosgenin (IC50 = 32.33 μM). In addition, 12e had weak cytotoxicity on the normal GES-1 cell line (IC50 = 213.74 μM). Moreover, 12e could cause G2/M cell cycle arrest, increase the percentage of apoptosis, induce mitochondrial depolarization, and promote reactive oxygen species generation in T24 cells. Further studies on antitumor mechanism demonstrated that 12e triggered the intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic pathways. More importantly, 12e could inhibit T24 cell proliferation in an in vivo zebrafish xenograft model. Therefore, 12e, as a novel trihybrid with potent cytotoxicity, might be applied as a promising skeleton for antitumor agents, which deserved further optimization., (Copyright © 2021 Elsevier Ltd. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF